Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod

Shelby L. Kubicki, Katherine E. Park, Phyu P Aung, Madeleine Duvic

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Primary cutaneous anaplastic large cell lymphoma (pc-ALCL) is a CD30+ subtype of cutaneous T-cell lymphoma. It typically has a very favorable prognosis; however, traditional treatment can be expensive, invasive, and associated with significant adverse events. Imiquimod is a topical toll-like receptor approved by the Food and Drug Administration (FDA) for genital warts, actinic keratosis, and primary superficial basal cell carcinoma. In previous case reports, imiquimod has been shown to be effective against pc-ALCL. We present a case of complete resolution of pc-ALCL within 8 weeks with topical imiquimod and review the current literature. J Drugs Dermatol. 2019;18(5):460-462.

Original languageEnglish (US)
Pages (from-to)460-462
Number of pages3
JournalJournal of drugs in dermatology : JDD
Volume18
Issue number5
StatePublished - May 1 2019

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod'. Together they form a unique fingerprint.

  • Cite this